Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives

Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives

Cinzia Federico, Valeria M Morittu, Domenico Britti, Elena Trapasso, Donato CoscoDepartment of Health Sciences, Building of BioSciences, University “Magna Græcia” of Catanzaro, Campus Universitario “S Venuta”, Germaneto, ItalyAbst...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Federico C, Morittu VM, Britti D, Trapasso E, Cosco D
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/022316115b5642f0a3c1beb424f85160
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:022316115b5642f0a3c1beb424f85160
record_format dspace
spelling oai:doaj.org-article:022316115b5642f0a3c1beb424f851602021-12-02T05:02:52ZGemcitabine-loaded liposomes: rationale, potentialities and future perspectives1176-91141178-2013https://doaj.org/article/022316115b5642f0a3c1beb424f851602012-11-01T00:00:00Zhttp://www.dovepress.com/gemcitabine-loaded-liposomes-rationale-potentialities-and-future-persp-a11406https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Cinzia Federico, Valeria M Morittu, Domenico Britti, Elena Trapasso, Donato CoscoDepartment of Health Sciences, Building of BioSciences, University “Magna Græcia” of Catanzaro, Campus Universitario “S Venuta”, Germaneto, ItalyAbstract: This review describes the strategies used in recent years to improve the biopharmaceutical properties of gemcitabine, a nucleoside analog deoxycytidine antimetabolite characterized by activity against many kinds of tumors, by means of liposomal devices. The main limitation of using this active compound is the rapid inactivation of deoxycytidine deaminase following administration in vivo. Consequently, different strategies based on its encapsulation/complexation in innovative vesicular colloidal carriers have been investigated, with interesting results in terms of increased pharmacological activity, plasma half-life, and tumor localization, in addition to decreased side effects. This review focuses on the specific approaches used, based on the encapsulation of gemcitabine in liposomes, with particular attention to the results obtained during the last 5 years. These approaches represent a valid starting point in the attempt to obtain a novel, commercializable drug formulation as already achieved for liposomal doxorubicin (Doxil®, Caelyx®).Keywords: gemcitabine, liposomes, multidrug, poly(ethylene glycol), tumorsFederico CMorittu VMBritti DTrapasso ECosco DDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2012, Iss default, Pp 5423-5436 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Federico C
Morittu VM
Britti D
Trapasso E
Cosco D
Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives
description Cinzia Federico, Valeria M Morittu, Domenico Britti, Elena Trapasso, Donato CoscoDepartment of Health Sciences, Building of BioSciences, University “Magna Græcia” of Catanzaro, Campus Universitario “S Venuta”, Germaneto, ItalyAbstract: This review describes the strategies used in recent years to improve the biopharmaceutical properties of gemcitabine, a nucleoside analog deoxycytidine antimetabolite characterized by activity against many kinds of tumors, by means of liposomal devices. The main limitation of using this active compound is the rapid inactivation of deoxycytidine deaminase following administration in vivo. Consequently, different strategies based on its encapsulation/complexation in innovative vesicular colloidal carriers have been investigated, with interesting results in terms of increased pharmacological activity, plasma half-life, and tumor localization, in addition to decreased side effects. This review focuses on the specific approaches used, based on the encapsulation of gemcitabine in liposomes, with particular attention to the results obtained during the last 5 years. These approaches represent a valid starting point in the attempt to obtain a novel, commercializable drug formulation as already achieved for liposomal doxorubicin (Doxil®, Caelyx®).Keywords: gemcitabine, liposomes, multidrug, poly(ethylene glycol), tumors
format article
author Federico C
Morittu VM
Britti D
Trapasso E
Cosco D
author_facet Federico C
Morittu VM
Britti D
Trapasso E
Cosco D
author_sort Federico C
title Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives
title_short Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives
title_full Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives
title_fullStr Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives
title_full_unstemmed Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives
title_sort gemcitabine-loaded liposomes: rationale, potentialities and future perspectives
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/022316115b5642f0a3c1beb424f85160
work_keys_str_mv AT federicoc gemcitabineloadedliposomesrationalepotentialitiesandfutureperspectives
AT morittuvm gemcitabineloadedliposomesrationalepotentialitiesandfutureperspectives
AT brittid gemcitabineloadedliposomesrationalepotentialitiesandfutureperspectives
AT trapassoe gemcitabineloadedliposomesrationalepotentialitiesandfutureperspectives
AT coscod gemcitabineloadedliposomesrationalepotentialitiesandfutureperspectives
_version_ 1718400690626232320

Ejemplares similares